GSK currently has a limited supply of RabAvert in their distribution centers. Due to delays in the manufacturing process, RabAvert resupply dates have been pushed out from January 2017 to March 2017.
In an effort to manage existing inventory, GSK will continue to accept new orders for RabAvert, however these orders will be placed on backorder until resupply is received. GSK does have a limited supply of RabAvert in inventory and can make product available to physicians who are not able to order through a wholesaler/distributor and who need RabAvert for post-exposure prophylaxis in an emergency situation.
GSK believes that there is sufficient inventory in the W/D channels to meet market demand, however, when GSK has low supply or is out of stock, wholesalers and distributors often allocate available product to their customers due to GSK's backorder. The wholesalers' and distributors' allocation approach can vary and may be based on customer's historical demand.
2017-2018 GSK Influenza Vaccines
Havrix Adult is out of stock until May 2017
Rabavert supply is limited